Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide; hepatocellular carcinoma (HCC) accounts for 75%-85% of such diagnoses.1 Early-stage HCC is amenable to locoregional treatments including surgical resection, radiofrequency ablation, transarterial chemoembolization (TACE), Y90 radioembolization, and liver transplantation.2,3 Traditionally, locoregional therapies such as Y90 radioembolization have been limited to intermediate stage...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile